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Abdominal aortic aneurysm (AAA) is indicated when the diameter of the abdominal 
aorta is larger than 30 mm. The primary risk associated with AAA is an increased risk of 
aortic rupture, which is fatal in 68-90% of cases. Once a patient is diagnosed with AAA, the 
AAA is monitored via abdominal ultrasound. The rationale for the regular surveillance is that 
the risk of rupture is low for AAA, less than 55 mm in size, but increases dramatically in 
diameter larger than 55 mm. Early surgery on patients with smaller AAA diameters (lower 
risk of rupture) has a higher mortality rate than taking no action. Despite numerous 
researches done about prediction of AAA size, there is a lack of a design that quantifies the 
risk of surgery and rates of rupture and mortality at surveillances and integrates it with the 
process of decision making. This research addresses the necessity of integrating the rupture 
rate in different time periods. 
A Monte-Carlo simulation technique was applied to a growth model based on 
Bayesian Analysis to simulate 10,000 and 1,000,000 hypothetical patients. To ensure that the 
generated data correlated to the original data, the Cholesky decomposition was determined 
from the patient cohort data and applied to generation of characteristics of the hypothetical 
patients. The probability of each possible growth trajectory and cumulative risk of rupture is 
computed by Bayesian Analysis for each patient. Mortality and rupture rates are calculated 





Statistics System data for 2014. The risk of rupture increases in patients with increase in the 
size and the mortality rate increases with the time. 
Different protocols regarding the surgical intervention threshold, risk of surgery, and 
observation time limits were designed, and the effects of life expectancy simulated. 
Simulating all 10,000 and 1,000,000 hypothetical patients and comparing the results for 
different designed protocols and current available protocols in different countries, gave us a 
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BACKGROUND ON ABDOMINAL AORTIC ANEURYSM AND 
RESEARCH OBJECTIVES 
 
 Background on Abdominal Aortic Aneurysm (AAA) 
 Abdominal aortic aneurysm (AAA) is indicated when the diameter of the abdominal 
aorta is larger than 30 mm [1]. The primary risk associated with AAA is aortic rupture, 
which is fatal in 68-90% of cases [2-3]. AAA is generally asymptomatic, so most AAA 
diagnoses are from non-related abdominal ultrasounds or x-rays. Given that the prevalence of 
AAA is 2-8% in men over the age of 65 years old, [4-6] Britain, Australia, and the United 
States have implemented AAA screening programs at least for high-risk patients (patients 
with AAA size larger than 30 mm). 
Once a patient is diagnosed with AAA, the AAA growth in size is monitored via 
abdominal ultrasound with recommended surveillance every 3 - 60 months. The rationale for 
the regular surveillance of AAA size is that the risk of rupture is low (less than 3.2% per 
1,000 person-years) for AAA less than 55 mm in size but increases rapidly once the diameter 
is larger than 55 mm [7]. Therefore, the surveillance provides information about the current 
AAA diameter and the associated risk of rupture. 
1.1.1 Risk of AAA Prevalence and Rupture 
To understand the risk of AAA rupture, recent research has focused on the growth, 





Therefore, going under a screening/surveillance program is beneficiary and preventive. For 
example, the UK Multicentre Aneurysm Screening Study (MASS) took a single ultrasound 
screening scan from 70,000 random patients between 65-74 years old and after 13 years they 
observed a 42% reduction in mortality related to AAA rupture [9]. This result supports the 
theory that screening for AAA reduces mortality. 
One could ask then why patients do not go under surgery before the diameter gets 
large and the risk of rupture gets high. Several trials have been conducted to determine if 
early repair is more preventive in comparison to going under surveillance; the result show no 
significant difference between the two groups [2 and 10-13]. The mortality rate for surgical 
repair of un-ruptured AAA is less than 3% [13] but this is still better than the risk of rupture 
for small AAA (less than 3.2% per 1,000 person-years). 
1.1.2 Screening Protocols to Reduce AAA Mortality 
There are different obstacles regarding screening protocols and its frequency. One is 
patients’ compliance with surveillance protocols. While implementing AAA screening 
programs reduces the mortality rate of screening participants, the participation rates are not 
100% and can vary: there was 80% participation rate in the Multicentre Aneurysm Screening 
Study (MASS) [14], 45% in Northern Ireland [15] and 85% in central part of Sweden [16]. 
There are two types of factors that lead to the low rate of participation of patients: patient and 
organization factors. Patient factors, such as younger age, female sex, being married, higher 
level of education, greater income and shorter distance from the screening center [17-22] are 
associated with increased rates of screening. The organization of screening, the type of 





Another difficulty in recommending AAA surveillance, which is considered in this 
dissertation, is that the growth of AAA has a large amount of inter-patient variability. That 
is, the AAA in one patient may expand rapidly (and require more regular surveillance and 
more immediate surgical intervention) while the AAA in some patients may grow slowly and 
require years, or decades, before surgery is needed. There are several models that predict the 
growth rate using data gathered from patients in different places. The lack of a model that 
gives the patient an individual overview about the outcomes of the surveillance, the risks, 
and the benefits can be a vital reason in the low participation of the people in screening 
programs. 
1.1.3 AAA Management 
Life-style related factors and their contribution to AAA incidence, AAA size, and 
growth rate were investigated and confirmed in different studies. A population-based study 
based on a prospective cohort of 14,249 male participants diagnosed with AAA in Sweden 
focused on several modifiable life style factors such as smoking, dietary consumption, 
physical activity, other comorbidities, alcohol consumption, and obesity [24]. Results of that 
research revealed that smoking, higher body mass index (BMI), and cardiovascular diseases 
were associated with an increase in mean AAA size as well as a higher chance of AAA risk 
[24-26]. Forsdahl et al. also confirmed the association of smoking with the occurrence of 
AAA. They found that the odds of AAA were nearly 14 times higher in people who smoked 
more than 20 cigarettes per day compared to those who never smoked [27]. Continued 
smoking has been shown to increase the AAA growth rate by 20% to 25% by Powell et al. 
[28]. Smoking has been proven to be a significant factor in both increasing the incidence of 





 Interestingly, alcohol consumption (more than a glass of alcohol per day) and 
diabetes mellitus were shown to have an inverse effect on mean AAA size. Walking or 
bicycling for more than 40 minutes per day was associated with a 41% lower AAA hazard 
compared to never bicycling or walking [24]. The effects of using antibiotics in the 
management of AAA has been studied by Vammen et al. [29]. Comparing patients taking 
roxithromycin antibiotic with patients under placebo therapy, they found a decrease in the 
mean annual expansion rate of AAA aneurysms in the former group. However, given the 
known harms of using antibiotics in long term, more data is needed on this approach [30].  
There are several approaches regarding management of AAA patients including 
participating in a surveillance protocol, medical therapy (with beta-blockers), surgery and 
endovascular stenting. Some studies have shown that in patients with small to medium AAA 
sizes who have not undergone surgical intervention, medical therapy may be helpful [31].  
Despite the fact that there is no clear evidence to support the idea of treating 
cardiovascular diseases in order to lower the risk of AAA incident, growth rate, or rupture; 
Patients with previous experience of undergoing AAA repair observed a decrease in all-
cause mortalities after using statin in long term [32]. Also, according to 2005 ACC/AHA 
guidelines it is recommended that AAA patients control their blood pressure and lipids in the 
same manner that atherosclerotic disease patients are recommended to [33]. 
Repair methods consist of surgical repair or endovascular repair (insertion of an 
endograft into the lumen). Endovascular repair is preferred over open surgical repair in terms 
of risk and cost. Endovascular repair has 83% to more than 95% short term technical success 
[34-36] with mortality rate of 2.7% to 5.8% in major randomized trials [10, 13, and 37]. The 





shown to impact the mortality rate after the surgery [38-39]. Patients will have a faster 
recovery, shorter hospital stay, less blood loss, and return to baseline functional capacity 
after endovascular repair [30]. 
1.1.4 Modeling the Growth of AAA 
Although there has been research done about prediction of AAA size and rupture, 
there is a lack of a design that quantifies the risk of surgery and rates of rupture and mortality 
at surveillances and integrates it with the process of decision making. An accurate model that 
can predict the risks of rupture for each interval can help patients to make a better decision 
about whether, and when, to have a surgical intervention. Given an overview about the risks 
in every single interval, there would be no need for patients with different growth rates to 
participate in broad screening programs. 
The objective of this project is to simulate the effect of surveillance protocols – using 
a model that has been fit to patient data [1] – to identify the most preventive surveillance 
intervals based on the AAA growth characteristics of individual patients. 
 Study Objectives 
AAA surveillance reduces AAA mortality due to rupture by monitoring AAA size 
and recommending surgery once the risk of surgery is less than the risk of rupture. Due to the 
high level of inter-patient variability in AAA growth, the appropriate intervals of 
surveillance, the risks for an individual patient, and the AAA size at which an individual 
patient should go under surgery are unknown. Altering each one of these factors will change 
the whole treatment schedule. For example, one patient may need to get monitored every 6 
months while another one can wait for 2 years without any risk of rupture. Predicting the 





patients’ characteristics increases the accuracy of recommendation whether it is surveillance 
in future or it is surgical intervention. Given these facts, I proposed optimizing the AAA 
surveillance intervals for individual patients based on patient characteristics associated with 
AAA growth: age, surveillance history of AAA size measurement, D-dimer level, and 
diabetes status. 
The objectives of this research are separated into two major segments: model-based 
and population-based. In the model-based phase my goal was to examine all possible 
combinations of variables (risk of rupture, surgical intervention threshold, and surveillance 
frequency) to find the optimum surveillance protocol and surgical intervention 
recommendation. Whereas in the population-based phase, I extracted the optimum designed 
protocol from step one and compared it with currently available protocols that are being 
applied in different countries. 
In both approaches, the ultimate goals were: 
1) To determine the surveillance protocol that provides the greatest benefits (higher life 
expectancy, less surveillance, and fewer numbers of fatalities). 
2) To determine the AAA size at which surgical intervention provides the greatest benefits. 
1.2.1 Objective #1: The Optimum Designed Protocol (Model-based) 
There are models that capture the growth rate of AAA in patients [5-8]. Monitoring 
the AAA diameter in patients is essential to develop a descriptive model of AAA growth 
rate. Such models can then be used in simulations to predict the preventative effect of 
potential AAA surveillance [5-8]. But it is unknown how often the intervals of the screening 
should be, what the risk of rupture for an individual patient is, and at what size an individual 





and financial power will not choose the same way of surveillance and treatment. Therefore, 
identifying the most preventive surveillance intervals based on the characteristics of an 
individual patient is strongly needed. 
New surveillance protocols were designed and new surgical intervention thresholds 
were tested by changing different decisive factors in simulation. These new protocols 
integrated the size of AAA with the risk of rupture assigned to that size and then compared it 
to different risks of surgery. Risk of surgery was tested for 1% to 10% (1% increments), and 
then based on sensitivity analysis, was narrowed down to 0.5% to 5%. Surveillance period 
limit of 1, 2, 3, 5, 7.5, and 10 years were also tested on all different protocols. Surgical 
intervention threshold was considered to be 50 mm, 55 mm, and 60 mm in order to ensure a 
better insight of which can be more preventive. Simulating diverse protocols by applying 
different risks of rupture, risks of surgical intervention fatality, surveillance period limits, 
and surgical intervention thresholds enabled me to examine all possible combinations to 
reach the most optimum protocol. 
Different studies suggest 55 millimeters as the size threshold for surgical intervention 
for patients with AAA and do not recommend earlier surgical intervention [8-9]. Due to the 
lack of postmortem studies to check the size in which the rupture happened, and the small 
number of cohorts who went under current surveillance protocols, it is unclear whether 
smaller or larger threshold sizes for surgery is more efficient. Efficient here means having a 
higher life expectancy in comparison with no treatment case with respect to having less 
number of surveillances. The ideal outcome for each protocol is to recommend surgery right 
before rupture happens, but is this possible with setting 55 millimeters as the threshold of 





Suggesting two different sizes (50 and 60 millimeters) and simulating the behavior of all 
generated hypothetical patients in different protocols is required to answer this vital question. 
This is another important factor in the efficiency of the suggested protocol. 
I proposed using a model of AAA growth that has been fit to AAA growth data [1] to 
simulate the growth rate of AAA and predict the number of surveillances and benefits of 
different potential surveillance protocols. Simulations helped us to find variable non-
dominated solutions for different patients. According to the solutions, we could find the 
optimal surveillance program that provides the lowest number of surveillances with the most 
effectiveness (increase in life expectancy and decrease in the number of surveillances). In 
addition, these simulations could support patients with different characteristics that were not 
available in the previous study cohort. This designed protocol can help patients to know 
which protocol can prevent them from fatal surgeries after rupture. 
1.2.2 Objective #2: Current AAA Surveillance Protocols (Population-based) 
Observed size of AAA in the surveillance is the only decisive parameter in the 
recommendation of next surveillance interval in the current available surveillance protocols 
in different countries, such as the United States, United Kingdom, Norway, Sweden, New 
Zealand, Australia, and Italy [7]. There is significant inter-patient variability in the AAA 
growth rate, which makes these protocols less accurate in predicting the most efficient 
interval for next surveillance or surgery. For instance, surveillance protocol in the United 
States suggests patients with sizes between 30 and 35 millimeters to return for surveillance 






Table 1.1: AAA surveillance intervals by country [7]. 




































Italy 30-55 6 
 
If there are two patients with an AAA size of 34 millimeters, say patient A with a 
very fast growth rate and patient B with a constant or negative growth rate, will they have the 
same outcome if they follow the same protocol that is being followed in the United States? 
Patient A may reach the threshold size and even have a rupture before passing 3 years, while 
patient B will show the same or smaller size as previous surveillance. On the other hand, 
following the protocol that is being enforced in Britain, patient B will spend time and money 
on surveillances every year that he does not need. This is not the only problem with these 
protocols. Since having a large cohort of patients going under these surveillance protocols in 





confident that which protocol is more preventive and efficient. Simulating these protocols 
with an accurate growth model, using a vast cohort of generated hypothetical patients and 
different surgical intervention thresholds gave us the opportunity to compare the outcomes. 
Additionally, according to the optimum results of the model-based approach, we created a 
protocol with surveillance recommendations solely based on size and compared it to 









METHODOLOGY OF SIMULATION STEPS 
 
To accomplish the research aims of determining the most beneficiary surveillance 
protocol and the optimum AAA size for surgical intervention, I utilized Monte Carlo 
simulations to quantify the effects of varying the surveillance intervals and AAA size 
threshold for surgical intervention and integrate the risk of rupture in the process of 
recommending surveillances. 
There are four major phases to performing the Monte Carlo simulations (see 
Figure 2.1): 
 





• “Generating Hypothetical Patients” phase (Section 2.1) generates characteristics and 
covariate effects for hypothetical patients that mimic those observed in a clinical cohort. 
These characteristics and covariate effects are inputs for the AAA growth model.   
• In the second phase, the hypothetical data is used in a model of AAA growth to calculate the 
size of the abdominal aorta at different time intervals in the future (AAA Growth Simulation 
Model – Section 2.2). While all of the patients are 65 years old and above (the model is 
based on a cohort of screened patients with an inclusion criteria of 65 years), there are fair 
possibilities of natural death and sudden rupture (before reaching the rupture threshold) 
during the time of surveillances.  
• Therefore, the third phase is to simulate the natural death and sudden rupture outcomes for 
each individual (Post Screening AAA Growth, AAA Rupture, and All-Cause Mortality – 
Section 2.3).  
• In the fourth phase, Bayes’ theorem is applied to calculate the probabilities of different 
outcomes that can occur for an individual patient. Bayes’ theorem modifies the probability of 
an outcome at present time by the observations that have been done in the past (Section 2.4).  
 Hypothetical Patients’ Data Generation 
2.1.1 Generating the Patient Characteristics of Baseline AAA Size Diabetes Status, 
D-Dimer Protein Level, and Age 
The distributions of hypothetical patient characteristics were generated to mimic 
those of the clinical cohort. Three different characteristics were associated with AAA growth 
parameters in the clinical cohort: baseline AAA size, status of diabetes mellitus, and level of 





a fourth parameter. To expand the data that mimics the original cohort, I followed these 
steps: 
• Finding the correlation coefficients among four different characteristics 
I used the pre-built correlation function in “R”, which is called “cor”. This function 
gets two vectors as input and returns the correlation coefficient between them. All of the 
characteristics of the original cohort (299 patients) are vectors, so using the “cor” function 
for each two characteristics gives us the following results. 
Table 2.1 shows a weak correlation between different characteristics. The largest 
correlation is between the level of D-dimer protein and the baseline size, and we can say 
there is no correlation between the age and baseline size. 








Baseline Size 1.0000 0.0461 0.2798 -0.0075 
Diabetes Mellitus 0.0461 1.0000 -0.0896 -0.0980 
D-dimer Level 0.2798 -0.0896 1.0000 0.1540 
Age -0.0075 -0.0980 0.1540 1.0000 
 
• Building Cholesky decomposition matrix based on the correlation coefficients 
The Cholesky decomposition matrix can be used to transform independent random 
variables to non-independent random variable. I used the Cholesky decomposition matrix to 
impose the correlations observed in the clinical data onto the hypothetical patients. The first 
step in this process was to calculate the Cholesky decomposition matrix for the correlation 





The Cholesky decomposition matrix is a square matrix, which is built based on the 
coefficients matrix. Pre-built function of the Cholesky decomposition matrix is available in 
the “R” library; therefore, I used it to calculate the Cholesky decomposition matrix based on 
my coefficients from the previous part. This function is called “chol”. It gets the square 
matrix of correlation coefficients and returns the Cholesky matrix result (which is a square 
matrix too). 
• Generating four random values from the normal distribution (rnorm function in R) 
At this step four independent, normally distributed random variables are generated. 
This function is called “rnorm” in “R” and its inputs are number of normally distributed 
numbers desired, mean, and standard deviation. The output is the normally distributed 
random numbers generated. It is noticeable that mean is zero and standard deviation is one in 
default settings of “R”. For example, the “rnorm(2)” command in R gives two normally 
distributed random numbers with a mean equal to zero and standard deviation equal to one. 
• Multiplying preceding four normally distributed random numbers in Cholesky 
decomposition matrix 
I then had a vector of four normally distributed random numbers and the Cholesky 
decomposition matrix, which is a square matrix. The length of the vector is the same as the 
dimensions of the Cholesky decomposition matrix. Since it is a vector, I transposed the 
Cholesky decomposition matrix in order to perform the multiplication. The transpose of a 
matrix can be formed in “R” using a function called “t”, which gets a matrix and returns 
transpose of it. The importance of this step is about the Cholesky decomposition matrix. 
When you generate a vector consisted of normally distributed random numbers and multiply 





built that the correlation coefficients are based on. In other words, different columns in the 
product matrix have the same correlation between them as the original data. 
•  Finding Cumulative Density Function (pnorm function in R) 
To go back to the original cohort characteristics data and read the assigned data to 
each of the numbers in the matrix that I made in the previous part, I needed to do one more 
step. Elements in the vector of the previous part gave me the height of the probability density 
function. Since I had the cumulative density function of my characteristics, I needed to 
change the previous part’s output into probabilities. I applied a function that calculates the 
probability of a normally distributed random number to be less than the given number. This 
function is called “pnorm” in “R”. Input in this function is the vector of quantiles, mean, and 
the standard deviation, and the output is the cumulative density function. 
• Call back the data from each row in the original cohort (quantile function in R) 
All of the previous steps were needed to be done, so I can go back to the original 
cohort’s data and recall the characteristics for a hypothetical patient. These are called 
hypothetical patients because I built their characteristics by generating random numbers and 
then transforming them through the explained process so that they act like the original 
cohort. There is the original cohort’s data, consisting of different columns of four 
characteristics of the patients, and there is a vector of probabilities with the same number of 
columns. It is important that columns of the probabilities’ vector are consistent with the 
original cohort’s data in all of the steps. For instance, the first column in the original data 
represents baseline size in the original cohort. Therefore, the first column in the probability 
vector should demonstrate the baseline size’s probability. If I go through each column of the 





“Quantile” function in “R” has two inputs. One is the vector that you want to extract data 
from it and the other one is its related probability. It returns the value of the characteristic 
from the data based on the probability that you give. Therefore, I was able to recall all four 
characteristics for a patient. 
Repeating these steps 10,000 times generated four characteristics for 10,000 patients, 
knowing that their behavior is just similar to the original cohort. I tested the previous 
statement by plotting and comparing both the original and the generated data’s cumulative 
distribution functions (see Figures 2.2 through 2.4). The upper plots are for the original 
cohort and the lower plots show the generated hypothetical data. Table 2.2 shows the 
similarity between generated hypothetical data and the original cohort’s data. The only 
difference is the number of patients that I increased to have a more reliable analysis. 
Table 2.2: Median (q1, q3) of characteristics of original cohort and generated 
hypothetical data. 
 
Original Cohort (N=299) 
Hypothetical Patients 
(N=10,000) 
Median Baseline Size, mm 























Figure 2.2: Age cumulative distribution function for (top) 299 AAA subjects from 














Figure 2.3: Baseline size cumulative distribution function for (top) 299 AAA subjects 











Figure 2.4: D-dimer level cumulative distribution for (top) 299 AAA subjects from 
Western Australia and (bottom) hypothetical patients. 
2.1.2 Generating Covariates for Hypothetical Patients 
The growth model that I used [1] to predict the future AAA sizes has model 
parameters with covariate effects based on a patient’s characteristics. So it needs the patient 
characteristics of an individual to predict the growth rates of this individual patient. Given 





to the data (5,000 sets of covariate values), I was able to implement the same approach as I 
did for characteristics. The rationale behind this part is that I wanted to be able to have a 
growth trajectory (based on hypothetical characteristics and hypothetical covariates) assumed 
as actual trajectory for each individual (described in Section 2.3.1). 
•  Finding the correlation coefficients among eight different characteristics 
I applied the pre-built function called “cor” in “R” again for this part. This time my 
input was an 8 in 5,000 matrix; including seven covariates, which are used in the predicting 
model (explained later), and a deviation variable, which shows the effect of the noise of 
surveillance. 
• Building the Cholesky decomposition matrix based on the correlation coefficients 
Because I wanted to generate new hypothetical covariates for the hypothetical 
patients, I needed to use the Cholesky decomposition matrix again to be reliable on the 
original output of the model based on real patients. The “chol” function in “R” was built 
based on the correlation matrix given by the previous step.  
• Generating 8 random values from the normal distribution (rnorm in R) 
There were seven different covariates in the data set plus one deviation factor; 
therefore, I needed to generate eight random values. The “rnorm” function in “R” is used to 
do so as. This function is completely explained in the Section 2.1.1.  
• Multiplying preceding 8 normally distributed random numbers in the Cholesky 
decomposition matrix 
Again, it was a vector of eight normally distributed random numbers that I wanted to 
multiply in the Cholesky decomposition matrix. I used “t” function to make it possible for 






• Finding Cumulative Density Function (pnorm in R) 
I used “pnorm” function in “R” to change the height of the probability density 
function to the cumulative density function to be able to use the original data set (posterior) 
to call back the generated data. 
• Call back the data from each row in the original data set (quantile function in R) 
All the previous steps made it possible to go to the posterior matrix of covariates that 
I had from the output of WinBUGS and recall the assigned parameter to each hypothetical 
patient. 
Implementing these steps 10,000 times results in having a matrix of correlated 
posterior values, which includes the required covariates needed to calculate the parameters in 
the growth model and the deviation factor used in observations. 
These parameter values for 𝑘th Markov chain Monte Carlo iteration, and the 𝑖th 
hypothetical patient are 𝛽0,𝑘
(𝑖)
 for baseline AAA size, 𝛽1,𝑘
(𝑖)
 for baseline AAA growth rate, and 
𝛽2,𝑘
(𝑖)
 for constant first derivative of AAA growth rate with size. I used these formulas to 








































where 𝑌𝑖(0) is the baseline AAA size measurement, 𝐶
(𝐷−𝑑𝑖𝑚𝑒𝑟) is plasma D-dimer 
concentration, and Diabetes is the diabetes status for the 𝑖th patient. In the posterior matrix, 















 are available and 𝛽0,𝑘
(𝑌(0))
 is the baseline AAA size of the patient, 
which is provided in the characteristics data. Therefore, I could use the hypothetical 
covariates to calculate the hypothetical parameters in the growth model. Table 2.3 shows the 
median values (Q1, Q3) of final model’s fixed parameters and the median values (Q1, Q3) of 
generated hypothetical covariates and its similarity to the original data. Table 2.4 shows the 















 denotes covariate effect of baseline AAA size 
measurement on baseline AAA size model parameter 
32.6 (32.5, 
32.7) 
32.6 (32.5, 32.7) 
𝜷𝟏
(𝟎)
 denotes offset from covariate effects for baseline 
AAA growth rate model parameter 
-1.61 mm/year        
(-3.08, -0.30) 




 denotes covariate effect of baseline AAA size 
measurement on baseline AAA growth rate model 
parameter 
2.03 mm/year    
(0.87, 3.40) 




 denotes covariate effect of plasma D-
dimer concentration on baseline AAA growth rate 
model parameter 
0.90 mm/year    
(0.11, 1.64) 




 denotes offset from covariate effect of baseline 
AAA size measurement on first derivative of AAA 
growth rate with size model 
-1.05/year               
(-1.52, -0.53) 




 denotes covariate effect of baseline AAA size 
measurement on first derivative of AAA growth rate 
with size model parameter 
0.59/year          
(0.11, 1.03) 




 denotes covariate effect of plasma D-
dimer concentration of first derivative of AAA growth 
rate with size model 
0.37/year          
(0.13, 0.62) 




 denotes covariate effect of diabetes status 
on first derivative of AAA growth rate with size model 
parameter 
-0.32/year               
(-0.45, -0.18) 









Table 2.4: Median values (q1, q3) of the final model’s fixed parameters covariance 
matrix. 
Fixed Parameters Value 
𝝈𝜷𝟎
𝟐 =  ∑𝟏,𝟏 denotes variance of baseline AAA size model parameter 0.19 mm2 (0.13, 0.28) 
𝝈𝜷𝟏





𝟐 =  ∑𝟑,𝟑 denotes variance of first derivative of AAA growth rate 




𝟐 =  ∑𝟏,𝟐 denotes covariance between baseline AAA size and 
baseline AAA growth rate model parameter 
0.30 mm2/year (0.20, 
0.41) 
𝝈𝜷𝟎,𝜷𝟐
𝟐 =  ∑𝟏,𝟑 denotes covariance between baseline AAA size and first 
derivative of AAA growth rate with size model parameters 
-0.06 mm/year (-0.09, 
-0.03) 
𝝈𝜷𝟏,𝜷𝟐
𝟐 =  ∑𝟐,𝟑 denotes covariance between baseline AAA growth rate 
and first derivative of AAA growth rate with size model 
0.59/year (0.11, 1.03) 
2.2 AAA Growth Simulation Model 
The AAA growth simulation model used in this research is based on the output of a 
Bayesian analysis on the growth of screen-detected AAA in men by Sherer et al., 2012 [1]. 
Out of 875 men diagnosed with AAA (above 30 mm) in a Western Australia screening, 299 
were followed with serial AAA diameter measurements. This model is based on this 299 
patient cohort who were followed for a median of 5.5 years and provided a median of 6 AAA 
size measurements per patient. Table 2.5 shows the characteristics that are used in the model 
and will be used in this study. The explanation of the growth model, characteristics, and 






Table 2.5: Characteristics of patients included in the simulation model [1]. 
Characteristic Value 
Number of men 299 
AAA diameter at baseline, median (q1, q3) 32.7 mm (30.8, 36.0) 
Duration of follow-up, median (q1, q3) 5.5 years (5, 6) 
AAA measurements per patient, median (q1, q3) 6 (6, 7) 
Age, median (q1, q3) 72 years (69, 75) 
Diabetes, N (%) 42 (14%) 
D-dimer protein, median (q1, q3) 326 ng/ml (142,785) 
 Post-Screening AAA Growth, AAA Rupture, and All-Cause Mortality 
2.2.1 Simulation of AAA Growth for Individual Patients 
It is very important to know how an AAA grows in the upcoming years. Does it grow 
fast? Does it have a constant growth rate? Does it have a negative growth rate? All of these 
possibilities are vital for making a decision in the future of the patient. If the AAA is a fast 
grower, it will reach the threshold of surgery and rupture faster than a AAA that has a small 
or negative growth rate. Now that both characteristics and covariates were generated, I could 
generate the parameters for all the patients. Giving different values to t, provided us the size 
of the abdominal aorta in the future time (Section 1.1.3). 
I separated the growth model outputs into two different categories; one is what I 
assumed as actual growth trajectory, in which I used the generated hypothetical patients’ 
characteristics and correlated covariates. The other category which is modeled growth 
trajectory was also based on hypothetical patients’ characteristics, but this time I used 
WinBUGS posterior distribution from the clinical data as covariates. In this case we could 





we could compare and analyze the differences in size in future. Figure 2.5 shows the actual 
growth trajectory for one patient in grey, with modelled growth trajectories in black. A dense 
area of modelled growth trajectories can be seen when the number of modelled trajectories 
increase. 
 
Figure 2.5: AAA size versus time for 10 and 5,000 growth trajectories (actual growth 
trajectory: grey, modelled growth trajectory: black). 
2.2.2 Simulation of the Age of AAA Rupture for an Individual Patient 
For patients diagnosed with abdominal aortic aneurysm, even if their aorta diameter 
is less than the threshold for elective surgery, having a rupture is possible [10-12]. Therefore, 
I had to consider rupture as an outcome in the future of the patients. According to numerous 
researches in the past 30 years, I have found that the risk of rupture is highly related to the 
size of aorta. The largest cohort was for the Rescan 2013 meta-analysis by Bown et al. 2013 
[7], which showed a clear relationship between the baseline size and the rate of rupture. 





able to predict the time of rupture using the assigned risk of rupture to each size and use the 
Monte Carlo simulation to select when the AAA will rupture for each hypothetical patient. 
I used the Monte Carlo simulation to estimate the age at which a patient’s AAA will 
rupture. In the Monte Carlo simulation, we can determine the interval of quiescence (the time 
period in which nothing happens – which is the time until rupture here) based on the known 
state of system (AAA size) at the current time [40]. To know the state of system at the 
current time, we could use the AAA growth rate to predict the AAA size at any future time. 
Then to find the interval of quiescent, we needed the transition rates; a transition rate is a 
function of state that describes the occurrence that we were looking for, which is AAA 
rupture in this case. As I mentioned before, multiple studies during the past 30 years have 
shown that the size of abdominal aorta is the most effective factor in the risk of rupture [7]. 
The Rescan 2013 meta-analysis by Bown et al. 2013 [7] with a cohort of 15,471 patients 
quantified the relationship between the baseline sizes of abdominal aorta and the rupture rate. 
I adopted the data from their paper (for specific baseline sizes; 30 mm, 35 mm, 40 mm, 45 
mm, and 50mm) and fit the data in the most accurate way possible in Microsoft Excel (see 
Figure 2.6). The reason for fitting to data is because size is a continuous parameter and the 
size of the aorta can be any real number, and not only the exact numbers that I adopted from 
the Rescan study. Data was best fit using a fourth degree polynomial with R-squared value of 
1. The largest baseline size related to a rupture rate available in this study was 50 mm 
(because surgery is generally recommended around this size), but it is possible for abdominal 
aorta to grow more than 50 mm without rupture and surgical intervention. Despite the fact 
that extrapolating can be risky in predicting the behavior of a function at unknown points due 





unknown points, too, to be able to calculate the age of rupture for those patients who will 
have abdominal aorta larger than 50 mm without having rupture. I extrapolated this fourth 
degree polynomial up to 100 mm in size to check if it has any undesired behavior, such as 
fluctuations, but the function is monotonically increasing, which is fairly a good estimate 
since the risk of rupture increases with size in the available data.  
 
Figure 2.6: Rupture rate versus size. 
Determining the transition rate (rupture rate versus the abdominal aorta’s size) 
provided the quiescent interval as a function of the status of the patient (AAA size). The 
rupture age is the desired variable, but the transition rate function gives the rupture rate 
versus size. At this point we utilized the growth model function once again to relate the size 
to the time (age). In every step of the process we could use the growth model to find the size 
related to the age. If we consider 𝜏 as the current time and take a step equal to 𝑑𝜏 in time, we 





the period of (𝜏 , 𝜏 + 𝑑𝜏). The shortest period of time that was recommended to a patient for 
surveillance is one year; therefore, I decided to choose 𝑑𝜏 equal to three months to be fairly 
accurate and avoid further errors. In mathematical terms: 
𝑃(𝜏 + 𝑑𝜏|𝑥𝑡) = 𝑃(𝜏|𝑥𝑡)[1 − 𝑏(𝑥(𝑡 + 𝜏,  𝑥𝑡 ,  𝑡))], Eq. 2.4 
where 𝑏 is the transition rate (i.e., rupture rate) and 𝑥 is the AAA size which is a function of 
the growth rate which is dependent to the size at current point and time. Rearranging terms 
and dividing by 𝑑𝜏, letting 𝑑𝜏 → 0: 
𝑑
𝑑𝜏
𝑃(𝜏|𝑥𝑡) = −𝑃(𝜏|𝑥𝑡)[𝑏(𝑥(𝑡 + 𝜏,  𝑥𝑡,  𝑡)]. Eq. 2.5 
We know the fact that quiescence interval is greater than 0, so: 
𝑃(0|𝑥𝑡) = 1, Eq. 2.6 
and 
                       𝑃(𝜏|𝑥𝑡) = exp[− ∫ 𝑏(𝑥(𝑡 + 𝜏
′,  𝑥𝑡,  𝑡)
𝜏
0
𝑑𝜏′].  Eq. 2.7 
Giving the cumulative distribution function for the quiescence interval: 
𝐹(𝜏|𝑥𝑡) = 1 − exp [− ∫ 𝑏(𝑥(𝑡 + 𝜏′, 𝑥0, 𝑡)
𝜏
0
𝑑𝜏′] . Eq. 2.8 
Randomly selecting a uniformly distributed random variable 𝑅 on the cumulative 
distribution function, a sample value of the quiescence interval 𝑇 is then found from: 
𝑅 = 1 − exp [− ∫ 𝑏(𝑥(𝑡 + 𝜏, 𝑥0, 𝑡))
𝑇
0
𝑑𝜏], Eq. 2.9 
𝑅 − 1 = − exp [− ∫ 𝑏(𝑥(𝑡 + 𝜏, 𝑥0, 𝑡))
𝑇
0
𝑑𝜏], Eq. 2.10 
ln(1 − 𝑅) = − ∫ 𝑏(𝑥(𝑡 + 𝜏, 𝑥0, 𝑡))
𝑇
0





− ln(1 − 𝑅) = ∫ 𝑏(𝑥(𝑡 + 𝜏, 𝑥0, 𝑡))
𝑇
0
𝑑𝜏. Eq. 2.12 
I generated a uniformly distributed random variable, 𝑅 for each patient, and solved 
this equation to find the age of rupture, 𝑇. To solve this equation I had to use bisection 
method for root finding. I wrote the code in R with error precision of seven decimal points 
(Appendix B). For the ranges in bisection method I used the current age as lower limit and 
120 years as the upper limit, which is fairly rational since there are not many people who live 
past this age. This formula starts from time zero to time 𝑇, when the incident happens. With 
a little modification I can start from the current age (𝜆1) to the age when the AAA will 
rupture (𝜆2): 
− ln(1 − 𝑅) = ∫ 𝑏(𝑥(𝜏, 𝑥0))
𝜆2
𝜆1
𝑑𝜏. Eq. 2.13 
In the programming and calculations, I used trapezoid rule for small intervals to 
calculate the integrations for each step. The transition rate function is a fourth degree 
polynomial and with the function’s behavior in the desired interval, trapezoid rule could be 
an accurate method. 
2.2.3 Simulation of the Age of Non-AAA Related Mortality of a Patient 
Another likely occurrence that may happen to the patients in the study cohort is death 
by all non-AAA related causes. All the patients are above 65 years old, so non-AAA related 
death is a likely outcome. To calculate the age when patients die by non-AAA related causes, 
I had an easier approach. Using the Monte Carlo simulation this time, as I have had the 
mortality rate versus age given by National Vital Statistics System in 2014 [41], needed less 





To find the transition rate for death by natural causes, I used the data from National 
Vital Statistics System data of 2014 [41]. This data set gives the death rate per 10,000 
populations for specific ages. I first converted the death rates form per 100,000 populations 
to per person and applied an interpolating polynomial to the data with the most accurate 
function, because age is a continuous function. I adopted data for 50 to 90 years old men 
with 5 years intervals and fitted the data with sixth degree polynomial with R-squared value 
equal to 1 (see Figure 2.7). 
 
Figure 2.7: Death rate versus age. 
Equation (2.13) can be easily modified for natural cause death. The only differences 
are that the transition rate is the mortality rate (rather than the AAA rupture rate) and the 
mortality rate is a function of age, which increases uniformly with time (so the growth model 





− ln(1 − 𝑅) = ∫ 𝑏(𝑥(𝜏, 𝑥0))
𝜆2
𝜆1
𝑑𝜏, Eq. 2.14 
Where 𝜆1 is current age of the patient, 𝜆2 is natural death age, 𝑏 is the transition rate (i.e., 
mortality rate), and 𝑥 is the age at current time. Again, I generated 10,000 uniformly 
distributed random variables for each patient and used trapezoid rule and bisection method to 
solve the equation and fine the natural death age. 
After this section, I had the data of natural cause death and the age of rupture for each 
one of 10,000 patients in my data set, which gave me an overview about their future. 
 Application of Bayes’ Rule to Predict AAA Size 
with Age of an Individual Patient 
At the beginning of predicting the future of AAA size in a patient based on the 
patient characteristics, there are many potential growth paths dependent on the set of 
covariates that we used in the growth model. As mentioned before, I assumed the growth 
trajectory of a patient to be the actual growth trajectory if the generated characteristics and 
generated covariates are used in the growth model. The modelled growth trajectory is when 
the generated characteristics of a patient are used with the covariates from posterior matrix 
(WinBUGS posterior distribution from clinical data). Because there are 10,000 sets of 
characteristics and 10,000 sets of covariates generated, there are 10,000 different actual 
trajectories for each one of the hypothetical patients. It is important to note that this is just an 
assumption for further calculations and all other trajectories can be the actual trajectory for a 
specific patient. For each patient, using generated characteristics and 5,000 different 
covariates from posterior matrix, there were 5,000 different modelled growth trajectories. I 
used these trajectories to compare with the one which is assumed to be the actual growth 





equally likely to happen. As time passes and observations determine the actual size of 
abdominal aorta (the size which is read from the actual growth trajectory of the patient) the 
likelihood of other possible trajectories (modelled growth trajectories) can be computed. 
Trajectories with sizes more similar to the actual trajectory are more likely to happen and 
those with sizes far from the actual observation are less likely to be the actual trajectory of 
the patient. At the beginning, the probability of each trajectory was 
1
5000
, but after each 
observation, I could update this probability based on our observation, using the Bayes’ rule. 
According to the Bayes’, rule we can write: 
𝑝(j𝑖|𝐱) =  
𝑝(𝐱|j𝑖) 𝑝(j𝑖)
∑ 𝑝(𝐱|j𝑖) 𝑝(j𝑖)i
. Eq. 2.15 
Where 𝐱 is vector of size measurements and j𝑖 is the 𝑖
th  growth trajectory. This 
equation states that the probability of the 𝑖th trajectory (𝑝(j𝑖|𝐬𝐢𝐳𝐞𝐬)), given a specific size 
(observed size), is equal to the probability of that size, given the 𝑖th trajectory (𝑝(𝐬𝐢𝐳𝐞𝐬|j𝑖)) 
multiplied by the current probability of the 𝑖th trajectory (𝑝(j𝑖)) over the sum of probabilities 




. This number keeps getting updated during later observations and that is 
how the probability of trajectories close to the actual trajectory gets larger and the probability 
of the trajectories far from the actual observations gets smaller. To perform these updates I 
used “R” software. First, I had to determine the actual size based on the actual growth 
trajectory. For this purpose, once again, I used “rnorm” function. This time I did not want to 
generate randomly distributed numbers. I generated this number based on the distribution 
over that specific time on the actual growth trajectory. As input, I set the number of 





correlated posterior matrix. When I explained the formation of the correlated posterior 
matrix, I mentioned a column consisting of deviation (noise) in observations. Here is where 
we use the deviation to have the effect of noise in our calculations. The feedback of this 
function is the actual size at that specific time, centered on the actual growth trajectory. The 
next step was to compare this actual size in a specific time with other modelled growth 
trajectories to find the likelihood. In this step, I used “dnorm” function and set the actual size 
found in the previous step, and the size of the desired trajectory, to find the likelihood. 
Output of this function is the likelihood between the observation and the size in a modelled 
trajectory. Finally, I multiplied the previous probabilities in the likelihood of the modelled 
trajectory based on new observations and divide it by the sum. I repeated this approach each 
time I needed to do an observation and kept updating the probabilities of different 
trajectories. Another use of this approach in my research is calculating the cumulative risk of 
rupture. In Chapter 2.3, I explained how I found a function to relate the size in abdominal 
aorta to the risk of rupture. When the probability of each modeled growth trajectory is known 
at different observations, we can find the cumulative risk of rupture by multiplying the 
probabilities’ of different trajectories in the assigned risk of rupture for that specific size. We 
define the cumulative risk of rupture as: 
Cumulative Risk of Rupture = ∑ 𝑝(j𝑖|𝐱) Risk𝑖𝑖 . Eq. 2.16 
 By this calculation, I have an estimate about the risk of rupture in a patient based on 
5,000 different possible trajectories. This data is also updated based on actual observation, 








EXPERIMENTAL PROTOCOLS AND 
ANALYZING PARAMETERS 
 
The methods described in Chapter 2 can be used to generate actual growth 
trajectories, rupture ages and sizes, and non-AAA related mortality ages for hypothetical 
patients in addition to predict the likelihood of rupture for an individual patient.  In this 
chapter, I describe how I used this simulation model to address the questions about when 
patients should receive surgery and how often they should receive AAA surveillance. 
One of the objectives of this study was to identify the most effective surveillance 
protocol by integrating the effect of risk of rupture at each interval to recommend the next 
surveillance (Section 3.1). On the other hand, current surveillance protocols in different 
countries are solely based on the AAA size. These protocols recommend patients to return 
for another surveillance based only on the size that is observed at current observation. After 
extracting the most optimum surveillance protocol from the first phase (Section 3.1) we were 
able to compare it to current available protocols in different countries in the second phase 
(Section 3.2).   
In this section I will explain the procedure of simulation and decision making in both 
designed protocols and current available protocols. In the last section I will discuss the 





 Designed Protocols – Proposed Protocols by Integrating 
Risk of Rupture in Surveillance Intervals 
As The ultimate purpose of designed protocol is to integrate the risk of rupture in the 
process of decision making about surveillance intervals. Figure 3.1 shows the overall 
procedure of simulation by referring to each section in the methods. The smallest interval for 
surveillance, due to current protocols, is three months and, in medical terms, having 
surveillance in less than three months rarely happens. Therefore, the minimum time step in 
this procedure is three months. The simulation will stop if the patient reaches the end time, 
which is defined as the time he dies by natural causes (Section 2.3.3) or has a sudden rupture 
(Section 2.3.2). The other case that stops the simulation is when surgery happens: when the 
patient passes the AAA size threshold for surgery (50, 55, or 60 mm based on different 
simulations). After taking a step in time through the growth model, the cumulative risk of 
rupture (Section 2.4) is compared with the risk of surgery. If the risk of rupture is more than 
the risk of surgery, or if we reach the time limit without risk of rupture passing the risk of 
surgery, the patient should go for a surveillance which updates the probabilities (Section 
2.4). The size, in which patients go for surveillance, and the time of the intervals, were also 






Figure 3.1: Flow-chart of designed protocols (model-based). 
This procedure was implemented on 10,000 hypothetical patients, each having 5,000 
modeled trajectories with different risks of surgery and time limits for surveillance to check 
the effect of each of these two parameters on the results. Primary simulations have been 
conducted for 1% to 10%, with the increment of 1%. The highest variability in the results 
was associated to the smallest risks. Therefore, the simulations were narrowed down to 
0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 4%, and 5%. Time limits for the cases that the risk of 
rupture does not pass the risk of surgery are 1, 2, 3, 5, 7.5, and 10 years. Considering three 
different thresholds for surgery (50, 55, and 60 mm) gives us 144 different protocols for 
simulation. 
 Available Protocols – AAA Surveillance Protocols  
in Different Countries 
As mentioned in Chapter 1, because there is not a vast cohort of patients who have 
been under surveillance by these protocols, one cannot say which protocol has fewer deaths 





by using the accurate growth model that is available, as well as data of generated 
hypothetical patients, I simulated these protocols in the long term on a much larger 
population. I used the baseline AAA size in the hypothetical generated data as the first 
observation, and, according to the protocol, set the next observation. In this approach I only 
used the actual growth trajectory for each patient, because I did not have to calculate the 
cumulative risk of rupture based on modeled trajectories. I also set the threshold for surgery 
as 55 mm, so the patient will be recommended to go under surgery if he reaches the 
threshold during the observations (Figure 3.2). Doing this simulation on 1,000,000 
hypothetical patients by applying different protocols (see Table 1.1), provided me with the 
number of surveillances, number of surgeries, number of deaths caused by natural causes, 
and number of sudden ruptures. All these results can show how the outcome of these 
protocols are different and which one is the most preventive. Additionally, I did the 
simulation again by setting the surgical intervention threshold as 50 mm, to be able to answer 
my hypothesis on the credibility of the threshold for surgery. Setting surgical intervention 
threshold at 60 mm was not applied in this simulation. According to the preliminary results, 
60 mm did not lead to any benefit to patient’s life expectancy, surveillances, or number of 






Figure 3.2: Flow-chart of current protocols (population-based). 
 
To make a fair comparison between the optimum designed protocol from the model-
based simulations with the current available protocols in different countries, I needed to 
modify the designed protocol in a way that its basis is similar to current available protocols 
in different countries. In the designed protocols, the decision of when to do another 
surveillance on the patient is made by integrating risk of rupture and comparing it to the risk 
of surgery. However, in population-based simulations (and in reality) timing of next 
surveillance is based on the patients’ AAA size at current observation. Using records from 
the model-based simulations, I created a protocol like the ones that are being used in 
different countries. By analyzing the timing and the size in which patients went for 
surveillance in the most optimum outcome of model-based simulations, I categorized 
surveillances based on different AAA size slots. This enabled me to create surveillance 






 Analysis Parameters 
3.3.1 Outcome #1: Life Expectancy 
To point out the difference among protocols for surveillance in long term, I defined a 
parameter that compares the effectiveness of these protocols on the life expectancy of the 
patients. In this parameter, I compared the estimated lifetime of the patient with and without 
treatment. I had two different approaches toward fatality of sudden rupture;  
- worst-case scenario which assumed that 90% of those who experience sudden 
rupture die and 10% will survive (Figure 3.1)  
- and best-case scenario which considers fatality rate at 70% [1].  
Also 2% of those who go under surgery are assumed to die [13]. In no treatment 
scenario, I only used data from Section 3.2 and 3.3 to estimate the age that patients will die 
by natural causes or will have sudden rupture. Data regarding each patient going under 
surveillance protocols were also available in the designed protocols, so the change in lifetime 
could be calculated in this case too: 
Change in Life Expectancy(Patienti)
=  Lifetimetreatment(Patienti)
−  Lifetimeno treatment(Patienti). 
Eq. 3.1 
3.3.2 Outcome #2: Number of Surveillances 
Change in life Expectancy by itself is not a complete metric for the comparison of 
different protocols.  For example, a patient may go under surveillance every 3 months and go 
under surgery right before the time of sudden rupture. Excessive number of surveillances is 
not desired because it is not possible for patients due to economic issues and patients’ 





efficiency in each protocol. By focusing on this parameter, it is possible to compare two 
protocols more accurately. The most preventive protocol is considered to be the one with 
highest increase in life expectancy and fewer number of surveillances at the same time.  
3.3.3 Outcome #3: Number of Ruptures 
Sudden rupture, if happens before natural death or elective surgery, is the least 
desired outcome of the simulation because it is highly fatal [2-3]. A higher ratio of the 
number of surgeries to the number of sudden ruptures is preferred, because it recommends 
patients to go under surgery before the rupture happens. In other words, in the timeline of the 
events, the most preventive protocol suggests elective surgery right before the rupture 
happens. However, it is really important to note that in population-based simulation this 
parameter (number of sudden ruptures) loses its value. This is because when surgery is being 
recommended solely based on size and not the calculated risk of rupture, number of sudden 
ruptures are independent from simulation. 
 Analysis on the Results 
3.4.1 Primary Analysis: Pareto Fronts 
Increased life expectancy is the most important goal of the treatment protocols. 
Patients spend time and money on surveillances and take the risk of surgery in order to 
increase their life expectancy but there are always constraints that should be considered. 
Keeping an eye on increase in life expectancy in a protocol, the efficiency of that protocol 
should be examined too. Having surveillances too often can obviously leads into an increase 
in life expectancy but it comes with expense of time and money for unnecessary 
surveillances that could have been avoided. An effective model should be efficient at the 





surveillances that each patient goes through (defined in Section 3.3.2). This factor gives us 
an idea if a protocol is increasing its effectiveness by increasing the number of surveillances 
unnecessarily (which is not desired). The last parameter (number of sudden ruptures) also is 
a valuable measure to evaluate a designed protocol. This parameter is useful in designed 
protocol analysis, because cumulative risk of surgery was calculated in different periods. 
However, in current protocols (population-based analysis) this factor is not decisive since 
decision making for surveillance or surgery is only based on AAA size and not a comparison 
risk of rupture and surgery. 
To evaluate protocols both in model-based and population-based simulations, I used a 
series of two-dimensional plots with the combination of three analyzing parameters; change 
in life expectancy, number of surveillances, and number of sudden ruptures. In each of three 
plots, I distinguished the protocols that reside on the Pareto Fronts. These are protocols that 
are non-dominated by others with respect to analyzing parameters. For example, in the plot 
of increase in life expectancy versus number of surveillances, protocols that have higher 
increase in life expectancy while keeping the number of surveillances fewer are considered 
non-dominated. Protocols that were available in all Pareto Fronts (model-based) and on two 
(population-based) were considered to be the most optimum protocols regarding decisive 
factors. 
3.4.2 Secondary Analysis: Patient Categories 
Categorizing patients based on their characteristics (age, AAA size, and diabetes 
mellitus status) and then observing how they benefited from a treatment protocol give 
significant insight about the effectiveness of each protocol. For instance, if patients with 





simulation on all protocols were combined and then divided into different groups based on 











Results of this research are separated into two phases. The first phase is model-based 
simulations performed on 10,000 hypothetical patients to identify optimum surveillance 
protocol. The second phase is a population-based analysis, which applies the optimum 
protocol of the model-based analysis to a larger population. Simulations were performed on 
10,000 hypothetical patients through designed protocols and for 1,000,000 hypothetical 
patients through the most optimum outcome (protocol) as well as current protocols followed 
in seven different countries. For each category of simulation, the timing and number of 
surveillances, ruptures, surgeries, and deaths by natural causes were measured. Based on 
these measurements, I analyzed which surveillance protocol leads to the highest life 
expectancy while keeping the number of surveillances and sudden ruptures as low as 
possible. In the designed protocols, the AAA size at each recommended observation and the 
time interval between observations, were recorded for each hypothetical patient. These data 
provided us the opportunity to address the objectives of this research on identifying the 
surveillance protocol and surgical intervention threshold that provides the greatest benefits 
(higher life expectancy, fewer surveillances, and fewer number of fatalities). 
In the first section of this chapter (Section 4.1), results of the model-based analysis, 





tables (including the best protocol) are reported here in Section 4.1.1 and the results of the 
rest of the protocols can be found in appendix A. 
The second section of this chapter (Section 4.2) is assigned to the population-based 
analysis which using the methods of Section 3.4.2, was performed on the most optimum 
protocol from the model-based simulation and protocols that are currently being enforced in 
different countries. The results of the second analysis on the designed protocols are available 
in Section 4.2.1. 
 Model-based Analysis Results 
4.1.1 Designed Protocols  
All analysis parameters explained in Section 3.3 (increase in life expectancy, number 
of surveillances, and number of sudden ruptures) are summarized in tables for all 144 
designed protocols. This gives a better look on how different designed protocols led to 
different outcomes in term of increase in life expectancy, number of surveillances, and 
number of ruptures. 
Tables 4.1 to 4.3 show the results for varying the AAA size threshold of surgery of 
50, 55, and 60 mm, respectively for 7.5 years time limit. Results for 7.5 years time limit were 
chosen because it includes the optimum protocol. Each surgery size threshold was tested as 
part of eight different protocols varying the estimated risk of surgery. The minimum time 
limit between observations was varied from 1 year to 10 years. Detailed results of all other 





Table 4.1: Simulation results for effects of varying the surgical intervention risk for 7.5 
years observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
167 184 202 173 207 189 239 268 
Number of 
Surgeries 




6935 7020 7092 7199 7204 7290 7312 7385 
Sum of Life 
Expectancies 
6993 6911 6657 6394 6510 6492 6258 6140 
 
 
Table 4.2: Simulation results for effects of varying the surgical intervention risk for 7.5 
years observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
216 248 248 224 222 244 269 280 
Number of 
Surgeries 




7450 7562 7542 7595 7636 7655 7706 7740 
Sum of Life 
Expectancies 







Table 4.3: Simulation results for effects of varying the surgical intervention risk for 7.5 
years observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
271 298 305 310 316 323 316 346 
Number of 
Surgeries 




7828 7888 7933 7930 7977 7951 7972 7990 
Sum of Life 
Expectancies 
6263 6041 5716 5932 5987 5807 5865 5779 
 
 
Figures 4.1 through 4.3 show the simulation outcomes of all 144 designed protocols 
for life expectancy versus number of surveillances, life expectancy versus number of 
ruptures, and number of surveillances versus number of ruptures, respectively. Figures 4.1 
through 4.3 are based on aggressive approach in analysis, in which, fatality rate of sudden 
rupture was assumed to be 90%. This will be discussed in more details in sensitivity analysis 
section.  
Data points on each Pareto front were distinguished by size (Figure 4.1), filling 
(Figure 4.2), and diamond shape (Figure 4.3). There is one protocol which is available on all 
three Pareto fronts (large filled diamond data point). This unique protocol suggests 50 mm as 
the threshold for surgery, 7.5 years as the threshold for surveillance, and 0.5% as the decisive 






Figure 4.1: Increase in life expectancy versus number of surveillances for 90% rate of 
fatality after AAA rupture (larger data points are non-dominated). 
 
 
Figure 4.2: Increase in life expectancy versus number of ruptures for 90% rate of 






Figure 4.3: Number of surveillances versus number of ruptures for 90% rate of 
fatality after AAA rupture (diamond shaped data points are non-dominated). 
 
The features of protocols that are non-dominated in at least two of the three outcomes 
(e.g. appear on the Pareto front in at least two of the Figures 4.1 to 4.3 are listed in Table 4.4. 
All the protocols available on the Pareto fronts apply the 50 mm as the threshold for surgery. 
Therefore, these protocols provide higher life expectancy, fewer number of surveillances, 






































50 mm 7.5 years 0.5% 6,993 years 2.72 0.0167 ✓ ✓ ✓ 
50 mm 10 years 2.5% 6,726 years 0.82 0.0179 ✓  ✓ 
50 mm 10 years 3% 6,326 years 0.77 0.0229 ✓  ✓ 
50 mm 10 years 5% 5,967 years 0.74 0.0236 ✓  ✓ 
50 mm 1 years 0.5% 6,630 years 9.54 0.0143  ✓ ✓ 
  
Increasing surgery threshold to 55 mm in the optimum protocol results in 5% 
decrease in life expectancy, 31% increase in number of surveillances, and 29% increase in 
number of ruptures. For 60 mm the differences are even greater (10% decrease in life 
expectancy, 60% increase in number of surveillances, and 62% increase in number of 
ruptures).  
The surveillance time limit of 7.5 years gives the most beneficial outcome. The 
surveillance time limit of 10 years for the optimum protocol may result in slightly less 
surveillances (-1%) and fewer ruptures (-4%), but it causes decrease in life expectancy (-
2.5%). The scenario is different for shorter surveillance time limits. Such protocols increase 
the number of surveillances and the number of ruptures while lowering the life expectancy, 
leading to a no-win situation. For instance, the life expectancy drops by 3% for 5 years, 6% 





protocol, while the numbers of surveillances rises by 6% for 5 years, 33% for 3 years, 79% 
for 2 years, and 250% for 1 year. The numbers of ruptures are also higher in the protocols 
with shorter surveillance time limits (1% for 5 years, 2% for 3 years, 5% for 2 years, and 
15% for 1 year). 
4.1.2 Sensitivity Analysis: Lower Rate of Fatality after AAA Rupture 
In a sensitivity analysis, the life expectancy versus number of surveillances (Figure 
4.4) and life expectancy versus number of ruptures (Figure 4.5) are plotted for the 
conservative approach, in which the fatality rate of rupture was considered to be 70%. The 
number of ruptures versus number of surveillances plot remain the same in both analyses, 
since these outcomes are independent from the fatality rate of rupture (Figure 4.4 and 4.5). 
Increase in life expectancy declined for all protocols. However, the order of protocols in term 
of increase in life expectancy and consequently optimum protocol did not change.  
 
Figure 4.4: Increase in life expectancy versus number of surveillances for 70% rate of 







Figure 4.5: Number of surveillances versus number of ruptures for 70% Fatality after 
AAA rupture (filled data points are non-dominated). 
 
4.1.3 Patient Benefits by AAA Baseline Size 
Categorizing patients based on different criteria gives a stronger understanding of 
which patients benefit more from the optimum protocols (Table 4.1). Patients with baseline 
size of 45 mm or higher experienced 4.97 years increase in their life expectancy in average 
under the optimum protocol. This number is 42% lower in patients with baseline size 
between 40 and 45 mm (2.89 years), 81% lower in patients with baseline size between 35 
and 40 mm (0.95 year), and 98% lower in patients with baseline size less than 35 mm (0.09 
year). This is due to the fact that in patients with smaller AAA size, it takes longer to reach 
surgical intervention threshold or rupture. Therefore, in patients with smaller AAA size, the 
difference in life expectancy with or without following surveillance and surgical protocol is 






Figure 4.6: Average increase in life expectancy based on AAA baseline size (all 
scenarios). 
 
Regarding the number of surveillances, patients with baseline size of 45 mm or 
higher went under 1.03 surveillances on average. Patients with baseline size of 40-45 mm 
went under 74% extra surveillances (1.8 surveillances). This number is 160% more for 
patients with baseline size of 35-40 mm (2.68 surveillances), and 211% higher for patients 
with baseline size less than 35 mm (3.21 surveillances). Other outputs (number of ruptures, 
surgical interventions and number of deaths due to natural cause) are also in favor of the 






Figure 4.7: Average number of surveillances based on AAA baseline size (all 
scenarios). 
 
4.1.4 Patient Benefits by Age 
There was a greater increase in life expectancy for patients who are diagnosed at 
younger ages (Figure 4.8). Patients younger than 70 years old averaged 0.98 year increase in 
life expectancy while older patients took less advantage of the optimum protocols (increase 
of 0.57 years for 70-75 years old, 0.27 years for 75-80 years old, and 0.10 years for >80 






Figure 4.8: Average increase in life expectancy based on age (all scenarios). 
 
Younger patients experience a greater number of surveillances since they live longer. 
Patients below 70 years of age averaged 3.53 surveillances. This number is 2.82 for patients 
between 70 to 75, 2.15 for 75 to 80, and 1.63 for patients older than 80 years old (Figure 
4.9). 
 






Another criterion that was analyzed was the diabetes status of the patients; the 
average increase in life expectancy is 0.79 years for non-diabetic patients versus 0.12 years 
for diabetic patients. 
 Population-based Analysis Results 
4.2.1 Optimum Designed Protocol versus Current Protocols 
The average time for a patient to go under surgery in the most optimum designed 
protocol (Table 4.1) is 6.95 years. Surveillance recommendations based on AAA diameter 
size is every 6.02 (SD 1.07) years for less than 35 mm, 3.73 (SD 0.80) years for 35-40 mm, 
2.09 (SD 0.45) years for 40-45 mm, and 1.16 (SD 0.24) years for 45-50 mm. Recommended 
timeline for surveillance based on AAA size in different countries can be seen in Table 1.1.  
Figures 4.10 through 4.12 illustrate the results of population-based simulation on the 
optimum designed protocol and protocols that are currently being enforced in 7 different 
countries; United States, New Zealand, Britain, Sweden, Norway, Italy, and Australia. Life 
expectancy versus number of surveillances, life expectancy versus number of ruptures, and 
number of surveillances versus number of ruptures are plotted in three two-dimensional 
plots. In this simulation 50 mm and 55 mm has been applied as the threshold for surgical 
intervention. Results from previous simulations proved that sizes larger than 55 (i.e. 60 mm) 






Figure 4.10: Increase in life expectancy versus number of surveillances for 7 
countries (larger data points are non-dominated). 
 
Figure 4.11: Increase in life expectancy versus number of ruptures for 7 countries 






Figure 4.12: Number of surveillances versus number of ruptures for 7 countries 
(diamond shaped data points are non-dominated). 
Results of the population-based simulation that was based on the optimum designed 
protocol and 7 protocols from different countries, along with their availability on Pareto 
fronts of Figures 4.10 through 4.12 are summarized in Table 4.5. With a closer attention to 
the number of ruptures it is obvious that this is irrelevant from the type of protocol that 
patients go under because the patient’s probability of rupture is essentially insensitive to their 
surveillance protocol. Focusing on the two factors that actually rely on the surveillance 
protocol (increase in life expectancy and number of surveillances) leaves us with three 
protocols: the optimum designed protocol from model-based simulation, the surveillance 































Designed 602,861 4.06 0.0222 ✓  ✓ 
Britain 615,206 14.69 0.0204 ✓ ✓  
Sweden 610,426 9.28 0.0204  ✓ ✓ 
Australia 606,341 14.29 0.0216  ✓  
Norway 612,644 9.28 0.0207 ✓   
New Zealand 601,444 10.85 0.0221    
Italy 609,832 21.18 0.0213    
US 608,078 9.27 0.0212    
  
4.2.2 Patient Benefits by AAA Baseline Size 
As it was done for model-based simulation, hypothetical patients were again divided 
into different groups based on their AAA baseline size, in order to have a greater 
understanding of which group benefits the most from surveillance protocols (Figure 4.13). 
Patients with baseline size of 45 mm or higher experienced 4.68 years increase in their life 
expectancy in average. This number is 2.84 years in patients with baseline size between 40 
and 45 mm (39% lower), 0.89 in patients with baseline size between 35 and 40 mm (81% 
lower), and 0.09 in patients with baseline size less than 35 mm (98% lower). The rationale 






Figure 4.13: Average increase in life expectancy based on AAA baseline size for 7 
countries (all scenarios). 
The same analysis on number of surveillances was performed with respect to 
patient’s AAA baseline size (Figure 4.14). Patients with baseline size of 45 mm or higher 
went under 2.55 surveillances on average. Patients with baseline size of 40-45 mm went 
under 5.54 surveillances (117% higher). This number is 9.62 for patients with baseline size 







Figure 4.14: Average number of surveillances based on AAA baseline size for 7 
countries (all scenarios). 
4.2.3 Patient Benefits by Age 
Categorizing the results with respect to age in this phase was consistent to model-
based simulation. Younger patients benefited more from going under surveillance compared 
to older patients (Figure 4.15). Average increase in life expectancy for patients younger than 
70 years old is 1.02 year. This number is 0.61 for those between 70 and 75, 0.29 for those 






Figure 4.15: Average increase in life expectancy based on age for 7 countries (all 
scenarios). 
Due to time limit, older patients go through fewer number of surveillances. Average 
number of surveillances is 12.52 for patients under 70, 10.11 for ones between 70 and 75, 
6.62 for ones between 75 to 80, and 4.04 for older than 80 (Figure 4.16). 
 









CONCLUSIONS, DISCUSSION, AND FUTURE WORK 
 
 Conclusions 
According to the results from model-based simulations (Section 4.1) and population-
based simulations (Section 4.2) going under surgery when the AAA diameter measures at 
least 50 mm increases life expectancy and reduces both the number of surveillances and the 
number of sudden ruptures. The 50 mm surgical threshold is smaller than the currently 
recommended threshold of 55 mm in the surveillance polices available in different countries 
[42]. In the study by Zarins et al. no rupture was seen in the group of patients with AAA size 
less than 50 mm with the survival of 89% at 5 years while it was 3% of rupture and 73% of 
survival in patients with AAA size from 50 to 59 mm [43]. Additionally, in a population-
based study, Nevitt et al. reported patients with AAA size smaller than 50mm free of rupture 
in the 5 year follow up despite the 5% annual risk of rupture for patients with AAA size 
larger than 50mm [44]. Even 3% of rupture is too high because of the high fatality rate upon 
rupture; waiting for surgery until the AAA is 55 mm increase the overall mortality rate. They 
also showed that in AAA sizes smaller than 50 mm there are fewer AAA-related deaths, 
surgical interventions, and secondary interventions. The fewer secondary interventions 
means that, if there is surgery at 55 mm, a patient is more likely to need a second surgery, 





surgery. Another significant factor weighing in for elective surgery (EVAR) in the earlier 
stage of the surveillance is that surgery was shown to have a better outcome in patients with 
smaller diameter compared to those with larger diameter [45-46]. 
The approach should not be either surgery for every patient with AAAs, nor a late 
surgical intervention which increases the risk of rupture in the patient. Different randomized 
trials have been conducted to identify the difference between early repair (open surgery or 
EVAR) and surveillance for patients diagnosed with abdominal aortic aneurysms. However, 
no significant difference in the outcome was observed [15, 47, and 48]. These studies show 
that the majority of patients in the surveillance group will go under surgery eventually 
(61.6% in Laderle et al., 60.9% in Powell et al., and 47.7% after 2 years in Cao et al.). 
Brewster et al. reported that “early surgery is comparable to surveillance with later surgery, 
so that patient preference is important, especially for AAA 4.5 cm to 5.5 cm in diameter” 
[42]. Finding a balance between frequency of the surveillances and the risk of rupture is the 
key to increase life expectancy while minimizing the number of surveillances. For example, 
in a recent study based on all AAA patients admitted to hospitals in Sweden in a 4-year 
period, Zommorodi et al. revealed the deficiency of current surveillance policies in 
comparison with non-diagnosed patients and recommended more individualized protocols 
based on patients [49]. We optimized the surveillance policies by quantifying the risk of 
rupture with respect to size and recommend the surveillance for patients based on patient’s 
unique growth trajectory. We found that the average number of surveillances per patient in 
the most optimum protocol is 2.72 which show that the increase in the life expectancy of the 






This study focused on integrating risk of rupture in decision making for surveillances 
to overcome the inter-patient variability in AAA growth that is neglected in current protocols 
offered in different countries. It also has generated a huge population of hypothetical patients 
to effectively analyze the outcomes like sudden rupture -that cannot be researched on with a 
large cohort because of ethical and logistical issues- or the correct size for surgical 
intervention threshold. Despite these efforts, there are always limitations that should be 
considered.  
Using the meta-analysis for our estimate of risk of rupture [7] might be one. Due to 
the lack of data for patients with AAA size above 50 mm, we used extrapolation to predict 
the risk associated with larger sizes. Numerous studies confirm the increase in risk of rupture 
with respect to increase in the AAA size, but assuming a lower rate of increase or even a flat 
rate from 50 to 60 mm may result in improved outcomes of larger AAA sizes to be 
considered the surgery threshold [13].  
The growth model that was used in this study was limited to a group of patients in 
Australia [13]. The growth model for Western-Australia in the meta-analysis fits fairly close 
to the consensus of the whole study cohort, which confirms the credibility of the model and 
utilization of the rupture risk from the same analysis.  
The post-surgery outcomes were simulated with respect to a few assumptions in this 
study. We assumed that patients are completely cured after the elective surgery and their 
quality of life has not been affected. This can be a reasonable assumption since Zarins et al. 
showed higher survival, no rupture, and fewer secondary interventions in patients with AAA 





Given the fact of high fatality in AAA ruptures, risking on postponing the repair does 
not seem to be reasonable. On the other hand, studies showed that early surgical intervention 
is not preventive. Therefore, a practical surveillance plan with a smaller recommended 
threshold for surgery and longer surveillance intervals (7 years, 6 years, 3.5 years, 2 years, 
and 1 year) is less risky and more preventive. 
 Future Work 
Cost-effective analysis is a potential research that can be conducted on the results of 
this study. In different sections of this study there are a couple of optimum solutions 
(protocols) on the Pareto front that one cannot be differentiated as the best protocol, because 
one is higher in one parameter (i.e. increase in life expectancy), and the other one is more 
beneficial in another parameter (i.e. number of surveillance). Considering the costs of 
surveillances in different times of a patient’s life, and the cost of surgical intervention, will 
















Table A.1: Simulation results for effects of varying the surgical intervention risk for 1 
year observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
143 173 147 169 150 158 173 152 
Number of 
Surgeries 




6945 6976 7013 6960 6969 6982 6947 6969 
Sum of Life 
Expectancies 
6630 6440 6663 6769 6408 6252 6426 6827 
 
 
Table A.2: Simulation results for effects of varying the surgical intervention risk for 1 
year observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
192 242 187 257 218 212 204 234 
Number of 
Surgeries 




7547 7521 7583 7508 7601 7585 7530 7539 
Sum of Life 
Expectancies 










Table A.3: Simulation results for effects of varying the surgical intervention risk for 1 
year observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
279 298 291 309 293 319 293 275 
Number of 
Surgeries 




7849 7866 7923 7915 7931 7920 7944 7931 
Sum of Life 
Expectancies 
6096 6055 6217 5819 6118 5859 5934 6129 
 
 
Table A.4: Simulation results for effects of varying the surgical intervention risk for 2 
years observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
158 162 168 152 180 157 180 185 
Number of 
Surgeries 




6978 7044 7047 7110 7093 7084 7057 7064 
Sum of Life 
Expectancies 










Table A.5: Simulation results for effects of varying the surgical intervention risk for 2 
years observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
235 241 243 259 232 266 230 250 
Number of 
Surgeries 




7533 7505 7544 7596 7622 7604 7691 7635 
Sum of Life 
Expectancies 
6344 6503 6446 6529 6340 6434 6378 6188 
 
 
Table A.6: Simulation results for effects of varying the surgical intervention risk for 2 
years observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
277 268 286 287 320 316 324 336 
Number of 
Surgeries 




7882 7866 7881 7903 7911 7954 7998 7963 
Sum of Life 
Expectancies 












Table A.7: Simulation results for effects of varying the surgical intervention risk for 3 
years observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
170 175 194 163 171 188 195 201 
Number of 
Surgeries 




6944 7020 7083 7173 7194 7204 7197 7162 
Sum of Life 
Expectancies 
6557 6958 6660 6625 6582 6633 6370 6857 
 
 
Table A.8: Simulation results for effects of varying the surgical intervention risk for 3 
years observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
217 244 234 269 227 269 261 264 
Number of 
Surgeries 




7494 7480 7615 7633 7652 7661 7662 7716 
Sum of Life 
Expectancies 









Table A.9: Simulation results for effects of varying the surgical intervention risk for 3 
years observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
266 280 275 274 302 313 327 339 
Number of 
Surgeries 




7877 7872 7954 7953 7915 7939 8004 7959 
Sum of Life 
Expectancies 
6150 6124 5934 5936 5999 6030 5976 5688 
 
 
Table A.10: Simulation results for effects of varying the surgical intervention risk for 5 
years observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
168 182 179 173 197 215 242 213 
Number of 
Surgeries 




6934 7024 7120 7199 7226 7297 7334 7362 
Sum of Life 
Expectancies 









Table A.11: Simulation results for effects of varying the surgical intervention risk for 5 
years observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
225 208 215 223 246 212 280 315 
Number of 
Surgeries 




7508 7570 7577 7579 7645 7679 7715 7729 
Sum of Life 
Expectancies 
6354 6334 6356 6466 6522 6277 5968 5912 
 
 
Table A.12: Simulation results for effects of varying the surgical intervention risk for 5 
years observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
273 308 320 307 330 342 322 313 
Number of 
Surgeries 




7833 7870 7912 7935 7916 7944 7947 8003 
Sum of Life 
Expectancies 









Table A.13: Simulation results for effects of varying the surgical intervention risk for 10 
years observation time limit and 50 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
174 175 186 191 179 229 241 236 
Number of 
Surgeries 




6920 7044 7162 7177 7203 7283 7313 7472 
Sum of Life 
Expectancies 
5198 5068 5218 4886 5138 4834 4645 4564 
 
 
Table A.14: Simulation results for effects of varying the surgical intervention risk for 10 
years observation time limit and 55 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
221 214 226 244 241 262 288 278 
Number of 
Surgeries 




7547 7524 7597 7619 7620 7632 7630 7766 
Sum of Life 
Expectancies 








Table A.15: Simulation results for effects of varying the surgical intervention risk for 10 
years observation time limit and 60 mm surgery threshold. 
Risk of 
Surgery 
0.5% 1% 1.5% 2% 2.5% 3% 4% 5% 
Number of 
Ruptures 
259 291 304 272 303 292 318 351 
Number of 
Surgeries 




7847 7890 7899 7937 7913 7938 7981 7949 
Sum of Life 
Expectancies 


































*** This code calculates correlation between elements of square 
matrix “x” with size “r” *** 
 
f.correlation <- function(x,r){ 
    cormatrix <- matrix(nrow=r,ncol=r) 
    for (i in 1:r){ 
        for (j in 1:r) { 
            cormatrix [i,j] <- cor(x[,i],x[,j]) 
        } 
    } 










*** This code recalls patients characteristics from original 
cohort based on uniformly distributed random numbers *** 
 
f.generate.bdda <- function(x,r,n){ 
    q <- matrix(ncol=r, nrow=n, 0) 
    bdda <- matrix(ncol=r, nrow=n, 0) 
    for (i in 1:n) { 
                b <- rnorm(r) 
            q[i,] <- t(chol(f.correlation(x,r))) %*% b  
            q[i,] <- pnorm(q[i,]) 
 
        bdda[i,1] <- quantile(x[,1],q[i,1]) 
        if (q[i,2] < sum(cohort[,2])/299) { 
            bdda[i,2] = 1 
        }   else { 
            bdda[i,2]=0 
            } 
        bdda[i,3] <- quantile(x[,3],q[i,3]) 
        bdda[i,4] <- quantile(x[,4],q[i,4]) 
} 









*** This code calculates the actual AAA size of the patient *** 
 
f.actual.size <- function(x,m,y,time){ 
    beta0k = 32.6*x[m,1]/median(x[,1]) 
    beta1k = y[m,2] + y[m,6]* x[m,1]/median(x[,1]) + y[m,4]* 
x[m,3]/median(x[,3]) 
    beta2k = y[m,3] + y[m,7]* x[m,1]/median(x[,1]) + y[m,5]* 
x[m,3]/median(x[,3]) + y[m,8]*x[m,2] 
    actual.size = (beta0k+ (beta1k-beta2k*beta0k)/beta2k)* 













*** This code calculates the modelled AAA size of the patient 
*** 
 
f.model.size <- function(x,m,y,n,time){ 
    model.size <- matrix(ncol=n, nrow=1) 
    for (i in 1:n){ 
        beta0k = 32.6*x[m,1]/median(x[,1]) 
        beta1k = y[i,2] + y[i,6]* x[m,1]/median(x[,1]) + y[i,4]* 
x[m,3]/median(x[,3]) 
        beta2k = y[i,3] + y[i,7]* x[m,1]/median(x[,1]) + y[i,5]* 
x[m,3]/median(x[,3]) + y[i,8]*x[m,2] 
     
        model.size[1,i] = (beta0k+ (beta1k-
beta2k*beta0k)/beta2k)* exp(beta2k*time) - (beta1k-
beta2k*beta0k)/beta2k 










*** This code estimates the natural death age of patients based 
on their age *** 
 
f.mortality <- function(x,m){ 
    p <- runif(1) 
    n <- 0 
    x_0 <- x[m,4]        
    x_l <- x[m,4]            
    x_u <- 120           
    x_m <- (x_l + x_u)/2     
    error <- 4.13*10^-7  
    epsilon <- 1         
    x_m2 <- 0 
    f_x_0 <- 1.4672444435E-09*(x_0)^7/7 - 5.8952338424E-
07*(x_0)^6/6 + 9.8293291496E-05*(x_0)^5/5 - 8.7017968341E-
03*(x_0)^4/4 + 4.3130650033E-01*(x_0)^3/3 - 
1.1346490352E+01*(x_0)^2/2 + 1.2376134495E+02*(x_0) 
 
    while (epsilon > error) 
    { 
        f_x_l <- 1.4672444435E-09*(x_l)^7/7 - 5.8952338424E-
07*(x_l)^6/6 + 9.8293291496E-05*(x_l)^5/5 - 8.7017968341E-
03*(x_l)^4/4 + 4.3130650033E-01*(x_l)^3/3 - 
1.1346490352E+01*(x_l)^2/2 + 1.2376134495E+02*(x_l) + log(1-p) - 
f_x_0 
        f_x_u <- 1.4672444435E-09*(x_u)^7/7 - 5.8952338424E-
07*(x_u)^6/6 + 9.8293291496E-05*(x_u)^5/5 - 8.7017968341E-
03*(x_u)^4/4 + 4.3130650033E-01*(x_u)^3/3 - 
1.1346490352E+01*(x_u)^2/2 + 1.2376134495E+02*(x_u) + log(1-p) - 
f_x_0 
        f_x_m <- 1.4672444435E-09*(x_m)^7/7 - 5.8952338424E-
07*(x_m)^6/6 + 9.8293291496E-05*(x_m)^5/5 - 8.7017968341E-
03*(x_m)^4/4 + 4.3130650033E-01*(x_m)^3/3 - 
1.1346490352E+01*(x_m)^2/2 + 1.2376134495E+02*(x_m) + log(1-p) - 
f_x_0 
     
        if (f_x_m * f_x_l > 0) 
            {   x_l <- x_m 
            } 
        if (f_x_m * f_x_u > 0) 
            {   x_u <- x_m 
            } 
     
        x_m2 <- (x_l + x_u)/2 
        epsilon <- abs((x_m2-x_m)/x_m2) 
        x_m <- x_m2 





    } 
    mortality.age <- x_m 





*** This code estimates the age when patients will have rupture 
based on their AAA size *** 
 
f.rupture.age <- function(x,y,m){ 
    p <- runif(1) 
    left_side <- -log(1-p) 
    beta0k = 32.6*x[m,1]/median(x[,1]) 
    beta1k = y[m,2] + y[m,6]* x[m,1]/median(x[,1]) + y[m,4]* 
x[m,3]/median(x[,3]) 
    beta2k = y[m,3] + y[m,7]* x[m,1]/median(x[,1]) + y[m,5]* 
x[m,3]/median(x[,3]) + y[m,8]*x[m,2] 
    dtau <- 1/365 
    tau <- 0 
    age <- x[m,4] 
    right_side <- 0 
     
        while(left_side>right_side & tau <55){ 
            size_old <- (beta0k + (beta1k-beta2k*beta0k)/beta2k) 
* exp(beta2k*tau) - (beta1k-beta2k*beta0k)/beta2k   
            rupture_rate_old <- 3.3866666667E-08*(size_old)^4 - 
4.4960000000E-06*(size_old)^3 + 2.2863333333E-04*(size_old)^2 - 
5.1762000000E-03*(size_old)^1 + 4.3930000000E-02 
            tau <- tau + dtau    
            size_new <- (beta0k+ (beta1k-beta2k*beta0k)/beta2k)* 
exp(beta2k*tau) - (beta1k-beta2k*beta0k)/beta2k     
            rupture_rate_new <- 3.3866666667E-08*(size_new)^4 - 
4.4960000000E-06*(size_new)^3 + 2.2863333333E-04*(size_new)^2 - 
5.1762000000E-03*(size_new)^1 + 4.3930000000E-02 
            right_side <- right_side + dtau * (rupture_rate_old 
+ rupture_rate_new) / 2 
} 
    T <- tau - dtau/2 
    rupture.age <- x[m,4] + T 









*** This code runs the overall simulation for population-based 
protocols and returns results *** 
 
for (i in 1:patients){ 
 
    time <- 0 
    age <- cohort1[i,4] 
    death.age <- f.mortality(cohort1,i) 
    rupture.age <- f.rupture.age(cohort1,corposterior,i) 
    end.time <- min(death.age,rupture.age) 
    actual.x <- cohort1[i,1] 
    surveillance <- 0 
    d <- 1 
    actual.x <- cohort[i,1] 
 
        while (age + time < end.time & actual.x < 55) { 
         
            tau <- 0 
 
            if (actual.x >= 25 & actual.x < 30){ 
                tau <- 5 
            } else if(actual.x >= 30 & actual.x < 35){ 
                tau <- 3 
            } else if(actual.x >= 35 & actual.x < 45){ 
                tau <- 1 
            } else { 
                tau <- 0.5 
            } 
 
        time <- time + tau 
        surveillance <- surveillance + 1 
     
        actual.size <-f.actual.size(cohort1,i,corposterior,time) 
        actual.x <- rnorm(1,actual.size,corposterior[i,1]) 
 
        surveillance_time[i,d] <- time 
         
        if (age + time < end.time) { 
            surveillance_size[i,d] <- actual.x 
        } 
        d <- d+1 
 
    } 
    result[i,1] <- age 
    result[i,2] <- death.age 
    result[i,3] <- rupture.age 





    result[i,5] <- surveillance 
    result[i,6] <- cohort1[i,1] 
} 
write.table(result, file="result_timeprotocol_55.csv", 
sep=",",row.names= FALSE, col.names=TRUE) 
write.table(surveillance_time, 
file="surveillance_t_timeprotocol_55.csv", sep=",", row.names= 
FALSE, col.names=TRUE) 
write.table(surveillance_size, 









*** This code runs the overall simulation for model-based 
protocols and returns results *** 
 
for (i in 1:patients){ 
     
    d <- 1 
    x_1_i <- x_1[i] 
    x_2_i <- x_2[i] 
    x_3_i <- x_3[i] 
    probability <- matrix(ncol=5000, nrow=1, 1/5000) 
    time <- 0 
    age <- cohort1[i,4] 
    death.age <- f.mortality(cohort1,i) 
    rupture.age <- f.rupture.age(cohort1,corposterior,i) 
    end.time <- min(death.age,rupture.age) 
    actual.x <- cohort1[i,1] 
    surveillance <- 0 
 
    while (age + time < end.time & actual.x <55){ 
 
        cumulative.risk <- 0 
        tau <- 0 
        dtau <- 1/4 
        integral <- matrix(ncol=5000, nrow=1, 0) 
 
        while (cumulative.risk < 0.005 & tau < 35) { 
            cumulative.risk <- 0 
            for (j in 1:5000){ 
                beta0k = 32.6*x_1_i/median_x_1 
                beta1k = y_2[j] + y_6[j]* x_1_i/median_x_1 + 
y_4[j]* x_3_i/median_x_3 
                beta2k = y_3[j] + y_7[j]* x_1_i/median_x_1 + 
y_5[j]* x_3_i/median_x_3 + y_8[j]*x_2_i 
 
                size_old <- (beta0k + (beta1k-
beta2k*beta0k)/beta2k) * exp(beta2k*(time + tau)) - (beta1k-
beta2k*beta0k)/beta2k  
                rupture_rate_old <- 3.3866666667E-
08*(size_old)^4 - 4.4960000000E-06*(size_old)^3 + 2.2863333333E-
04*(size_old)^2 - 5.1762000000E-03*(size_old)^1 + 4.3930000000E-
02 
             
                size_new <- (beta0k+ (beta1k-
beta2k*beta0k)/beta2k)* exp(beta2k*(time + tau + dtau)) - 
(beta1k-beta2k*beta0k)/beta2k     
                rupture_rate_new <- 3.3866666667E-





04*(size_new)^2 - 5.1762000000E-03*(size_new)^1 + 4.3930000000E-
02 
         
                integral[j] <- integral[j] + dtau * 
(rupture_rate_old + rupture_rate_new) / 2 
                cumulative.risk <- cumulative.risk + 
probability[j] * ( 1 - exp(-integral[j])) 
            } 
            tau <- tau + dtau 
        } 
        time <- time + tau 
 
         
        surveillance <- surveillance + 1 
             
        actual.size <- 
f.actual.size(cohort1,i,corposterior,time) 
        model.size <- 
f.model.size(cohort1,i,posterior,5000,time) 
        actual.x <- rnorm(1, actual.size, corposterior[i,1]) 
        numerator <- matrix(ncol=5000, nrow=1, 0) 
        for (k in 1:5000){ 
            likelihood <- dnorm(actual.x, model.size[1,k], 
posterior[k,1]) 
            numerator[k] <- likelihood * probability[k] 
        } 
        denominator <- sum(numerator) 
        probability <- numerator/denominator 
                         
 
        surveillance_time[i,d] <- time 
        if (age + time < end.time) { 
            surveillance_size[i,d] <- actual.x 
        } 
        d <- d+1 
 
    } 
 
    result[i,1] <- age 
    result[i,2] <- death.age 
    result[i,3] <- rupture.age 
    result[i,4] <- age + time 
    result[i,5] <- surveillance 
    result[i,6] <- cohort1[i,1] 
    result[i,7] <- corposterior[i,2] + corposterior[i,6]* 





    result[i,8] <- corposterior[i,3] + corposterior[i,7]* 







sep=",",row.names= FALSE, col.names=TRUE) 
write.table(surveillance_time, 
file="surveillance_t_0.005_1_10000_risk.csv", sep=",", 
row.names= FALSE, col.names=TRUE) 
write.table(surveillance_size, 
file="surveillance_s_0.005_1_10000_risk.csv", sep=",", 
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